{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:01:02Z","timestamp":1787504462339,"version":"build-2736575974"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:p>Myofibromas are rare fibroblastic-myofibroblastic tumors in children. Their biological behavior is unpredictable and spontaneous regressions have been described. This is a retrospective review of clinical characteristics, treatment, and outcome of children diagnosed with myofibroma between 1999 and 2013 at Texas Children\u2019s Hospital. The median age at diagnosis of 42 patients was 37 months. Approximately two thirds of the patients were male. The median length of follow-up was 50.5 months (range, 0 to 165 mo). Thirty-eight patients (90%) had solitary lesions; 19 (50%) in the head and neck, 10 (26%) in the limbs, and 9 (24%) in the trunk. Twelve patients underwent a complete surgical resection. Of the 30 patients with positive margins, only 1 had tumor progression. Two patients had multicentric involvement, and 2 patients had generalized disease with visceral involvement. One patient with generalized disease and a progressive maxillary sinus mass was treated with vinblastine and methotrexate chemotherapy followed by complete surgical resection. All patients were alive at last follow-up. Myofibromas of childhood demonstrate clinical variability, and may spontaneously regress. Positive surgical margins do not adversely affect outcome. The rare patient with progressive unresectable disease may benefit from chemotherapy.<\/jats:p>","DOI":"10.1097\/mph.0000000000000732","type":"journal-article","created":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T22:44:34Z","timestamp":1483656274000},"page":"e136-e139","source":"Crossref","is-referenced-by-count":23,"title":["Myofibroma in Infancy and Childhood"],"prefix":"10.1097","volume":"39","author":[{"given":"Priya","family":"Mahajan","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer Center, Texas Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hicks","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer Center, Texas Children\u2019s Hospital"},{"name":"Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Chintagumpala","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer Center, Texas Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajkumar","family":"Venkatramani","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Cancer Center, Texas Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0022-3468(88)80196-9","article-title":"Infantile myofibromatosis: the most common fibrous tumor of infancy","volume":"23","author":"Wiswell","year":"1988","journal-title":"J Pediatr Surg"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/1097-0142(19811015)48:8<1807::AID-CNCR2820480818>3.0.CO;2-G","article-title":"Infantile myofibromatosis","volume":"48","author":"Chung","year":"1981","journal-title":"Cancer"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1468-3083.2007.02292.x","article-title":"Self-healing generalized infantile myofibromatosis","volume":"22","author":"Martin","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.bjps.2006.01.019","article-title":"Involuting solitary cutaneous infantile myofibroma and thrombocytopaenia: a previously unreported clinical association","volume":"60","author":"Leon-Villapalos","year":"2007","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s004310050725","article-title":"Cure of infantile myofibromatosis with severe respiratory complications without antitumour therapy","volume":"156","author":"Zeller","year":"1997","journal-title":"Eur J Pediatr"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/1097-0142(195409)7:5<953::AID-CNCR2820070520>3.0.CO;2-W","article-title":"Juvenile fibromatoses","volume":"7","author":"Stout","year":"1954","journal-title":"Cancer"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/1097-0142(196504)18:4<460::AID-CNCR2820180410>3.0.CO;2-B","article-title":"Congenital mesenchymal tumors","volume":"18","author":"Kauffman","year":"1965","journal-title":"Cancer"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.yadr.2006.09.003","article-title":"An historic perspective of infantile myofibromatosis","volume":"22","author":"Matthews","year":"2006","journal-title":"Adv Dermatol"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000056059","article-title":"Intracranial infantile myofibromatosis with intraparenchymal involvement","volume":"36","author":"Kaplan","year":"2002","journal-title":"Pediatr Neurosurg"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2350\/10-12-0944-PB.1","article-title":"Fibroblastic and myofibroblastic tumors in children and adolescents","volume":"15","author":"Coffin","year":"2012","journal-title":"Pediatr Dev Pathol"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/mpo.1350","article-title":"Brief report: successful therapy of a patient with infantile generalized myofibromatosis","volume":"38","author":"Day","year":"2002","journal-title":"Med Pediatr Oncol"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/00043426-200309000-00016","article-title":"Successful treatment of life-threatening generalized infantile myofibromatosis using low-dose chemotherapy","volume":"25","author":"Gandhi","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"R13-20230918","first-page":"480","article-title":"Massive apoptosis in infantile myofibromatosis. A putative mechanism of tumor regression","volume":"144","author":"Fukasawa","year":"1994","journal-title":"Am J Pathol"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1080\/08880010500278780","article-title":"Successful treatment of relapsed multifocal nonvisceral infantile myofibromatosis","volume":"22","author":"Rossbach","year":"2005","journal-title":"Pediatr Hematol Oncol"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/MPH.0000000000000132","article-title":"Chemotherapy for generalized infantile myofibromatosis with visceral involvement","volume":"37","author":"Wu","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/pbc.21797","article-title":"First-line therapy of generalized infantile myofibromatosis with low-dose vinblastine and methotrexate","volume":"52","author":"Azzam","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/pbc.23387","article-title":"Risk-adapted therapy for infantile myofibromatosis in children","volume":"59","author":"Levine","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/MPH.0b013e31815e62bb","article-title":"Remission of infantile generalized myofibromatosis after interferon alpha therapy","volume":"30","author":"Auriti","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1001\/archderm.136.5.597","article-title":"Congenital generalized myofibromatosis in a neonate","volume":"136","author":"Dimson","year":"2000","journal-title":"Arch Dermatol"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.2006.08.2966","article-title":"Vinblastine and methotrexate for desmoid fibromatosis in children: results of a pediatric oncology group phase II trial","volume":"25","author":"Skapek","year":"2007","journal-title":"J Clin Oncol"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/MPH.0000000000000286","article-title":"Vincristine and dactinomycin in infantile myofibromatosis with a review of treatment options","volume":"37","author":"Weaver","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1067\/mjd.2003.333","article-title":"Infantile myofibromatosis: support for autosomal dominant inheritance","volume":"49","author":"Ikediobi","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1399-0004.1976.tb01602.x","article-title":"Congenital generalized fibromatosis: an autosomal recessive condition?","volume":"9","author":"Baird","year":"1976","journal-title":"Clin Genet"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/cncr.2820690537","article-title":"Familial occurrence of infantile myofibromatosis","volume":"69","author":"Bracko","year":"1992","journal-title":"Cancer"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.jpedsurg.2012.09.046","article-title":"Infantile myofibromatosis: report on a family with autosomal dominant inheritance and variable penetrance","volume":"47","author":"Kulkarni","year":"2012","journal-title":"J Pediatr Surg"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.ajhg.2013.04.026","article-title":"A recurrent PDGFRB mutation causes familial infantile myofibromatosis","volume":"92","author":"Cheung","year":"2013","journal-title":"Am J Hum Genet"},{"key":"R27-20230918","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.ajhg.2013.04.024","article-title":"Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis","volume":"92","author":"Martignetti","year":"2013","journal-title":"Am J Hum Genet"},{"key":"R28-20230918","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1038\/onc.2015.383","article-title":"PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib","volume":"35","author":"Arts","year":"2016","journal-title":"Oncogene"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201704000-00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T12:20:09Z","timestamp":1718972409000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201704000-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000000732","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}